Inventor · disambiguated record
Michael Alan Green
Also filed as: GREEN MICHAEL · GREEN MICHAEL A · GREEN MICHAEL ALAN
18 granted patents·17 pending applications·446 citations·filing 2001–2023
92Inventor score
Top patents by PatentIndex Score
35 records- 0197US6552065B2Deacetylase inhibitorsNOVARTIS AG·Filed 2001·Granted Apr 22, 2003·338 cites·27 claims
- 0291US7067551B2Deacetylase inhibitorsNOVARTIS AG·Filed 2004·Granted Jun 27, 2006·36 cites·9 claims
- 0391US6833384B2Deacetylase inhibitorsNOVARTIS AG·Filed 2002·Granted Dec 21, 2004·32 cites·8 claims
- 0490US8946415B2Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their useBI YINGZHI·Filed 2013·Granted Feb 3, 2015·17 cites·15 claims
- 0586US9403832B2Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their useLEXICON PHARMACEUTICALS INC·Filed 2014·Granted Aug 2, 2016·9 cites·6 claims
- 0686US8969565B2Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their useBI YINGZHI·Filed 2013·Granted Mar 3, 2015·11 cites·5 claims
- 0776US10590111B2Substituted 2-anilinopyrimidine derivatives as EGFR modulatorsBETA PHARMA INC·Filed 2015·Granted Mar 17, 2020·2 cites·39 claims
- 0869US12187707B2Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylaminde and salts thereofBETA PHARMA INC·Filed 2021·Granted Jan 7, 2025·0 cites·13 claims
- 0965US11180478B2Pharmaceutical formulations of N-(2-(2-(dimethylamino) ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereofBETA PHARMA INC·Filed 2018·Granted Nov 23, 2021·0 cites·15 claims
- 1063US2008176849A1Deacetylase inhibitorsREMISZEWSKI STACY WILLIAM·Filed 2008·Application pending·0 cites
- 1161US11414401B2Substituted 2-anilinopyrimidine derivatives as EGFR modulatorsBETA PHARMA INC·Filed 2020·Granted Aug 16, 2022·0 cites·7 claims
- 1260US2025276968A18- and 6-substituted pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2023·Application pending·0 cites
- 1359US10844045B2Pharmaceutical salts N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereofBETA PHARMA INC·Filed 2017·Granted Nov 24, 2020·0 cites·23 claims
- 1459US8304577B2Modulators of G protein-coupled receptor 88DZIERBA CAROLYN DIANE·Filed 2010·Granted Nov 6, 2012·1 cites·4 claims
- 1558US2009181992A1(s)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their useBARBOSA JOSEPH·Filed 2009·Application pending·0 cites
- 1658US2006189674A1Deacetylase inhibitorsREMISZEWSKI STACY W·Filed 2006·Application pending·0 cites
- 1758US2025250286A1Fused pyrimidine derivatives as kras oncoprotein inhibitorsBETA PHARMA INC·Filed 2022·Application pending·0 cites
- 1856US11052086B22-anilinopyrimidine derivatives as therapeutic agents for treatment of brain cancersBETA PHARMA INC·Filed 2017·Granted Jul 6, 2021·0 cites·7 claims
- 1954US2024140948A1Pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2022·Application pending·0 cites
- 2054US2009286820A1(r)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their useBARBOSA JOSEPH·Filed 2009·Application pending·0 cites
- 2153US12258365B2Organophosphorus-substituted compounds as c-MET inhibitors and therapeutic uses thereofBETA PHARMA INC·Filed 2019·Granted Mar 25, 2025·0 cites·30 claims
- 2252US2023099858A1Pyridopyrimidine derivatives as kras inhibitorsBETA PHARMA INC·Filed 2021·Application pending·0 cites
- 2351US2024002365A1Pyridazine and 1,2,4-triazine derivatives as fgfr kinase inhibitorsBETA PHARMA INC·Filed 2021·Application pending·0 cites
- 2450US12390464B2Treatment of EGFR mutant-related cancers using a combination of EGFR and CDK4/6 inhibitorsBETA PHARMA INC·Filed 2020·Granted Aug 19, 2025·0 cites·20 claims
- 2550US2008146600A1(s)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their useBARBOSA JOSEPH·Filed 2007·Application pending·0 cites
- 2650US2015175610A1PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USELEXICON PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2750US2008146596A1(r)-phenyl(heterocycle)methanol-based compounds, compositions comprising them and methods of their useBARBOSA JOSEPH·Filed 2007·Application pending·0 cites
- 2848US2017129896A1PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USELEXION PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2947US2017057964A1IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USELEXICON PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 3044US2016024093A1IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USELEXICON PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 3143US9862724B2Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their useLEXICON PHARMACEUTICALS INC·Filed 2016·Granted Jan 9, 2018·0 cites·13 claims
- 3242US2015183791A1IMIDAZO[1,2-b]PYRIDAZINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USELEXICON PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 3341US2008076788A1Solid forms of (3'-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone and methods of their useBARBOSA JOSEPH·Filed 2007·Application pending·0 cites
- 3434US8497271B2Modulators of G protein-coupled receptor 88BI YINGZHI·Filed 2010·Granted Jul 30, 2013·0 cites·15 claims
- 3534US8426414B2Modulators of G protein-coupled receptor 88BI YINGZHI·Filed 2010·Granted Apr 23, 2013·0 cites·7 claims
Join the waitlist — get patent alerts
Get an alert when Michael Alan Green files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →